• 学术搜索
  • 科研智能体
    • Research Labs
    • AI 阅读
    • AI 文库
    • 深度研究
    • 学者亮点
  • 学术资源
    • AI2000
    • 期刊/会议
    • 学者库
    • 学术API
      MCP&Skill
    • 溯源树
    • 数据集
  • 知识沉淀
    • 学术空间
订阅小程序
旧版功能
aminer vip
开通会员低至0.73元/天
一次搞定AI科研
立即登录
  • English
  • 联系方式
    I

    IRCCS Materno Infantile Burlo Garofolo,Istituti di Ricovero e Cura a Carattere Scientifico

    EST. 1992
    1,093论文总数
    1.3万引用总数

    论文量&引用量时间轴

    机构学者

    论文(1093)

    年份
    起
    –
    止
    排序
    1An International, Multicentre Validation Study of IOTA Ultrasound-Based Risk Models for the Assessment of Paediatric and Adolescent Adnexal Masses
    Nina Cooper,Ashleigh Ledger,Antonia Testa,Lil Valentin,Wouter Froyman,Robert Fruscio,Francesca Buonomo,Maya Al-Memar,Ben Van Calster,Dirk Timmerman,Tom Bourne
    2026BJOG-AN INTERNATIONAL JOURNAL OF OBSTETRICS AND GYNAECOLOGY(2026)
    引用
    AI阅读
    加入学术空间
    2The Anti-Gpc1 Antibody AT101 As Effective Targeting Agent for Chemotherapeutic-Loaded Chitosan Nanobubbles in the Treatment of Pancreatic Adenocarcinoma
    Davide Busato,Monica Argenziano,Maurizio Polano,Sara Capolla,Monica Mossenta, Carmela Tangredi,Federico Riccardi,Alessandro Mangogna,Paolo Durigutto, Giorgia Fontana,Luigina De Leo,Daniele Sblattero,

    Recently, we developed AT101, an IgM-class mouse monoclonal antibody directed against glypican-1 (GPC1), a proteoglycan considered as useful target for pancreatic adenocarcinoma (PDAC) treatment being specifically and highly expressed on PDAC cell surface. Here, we proposed AT101 as targeting agent to effectively deliver chitosan nanobubbles (NBs) for PDAC treatment. Different chitosan NB formulations were prepared with or without AT101 conjugation and doxorubicin loading. In PDAC-like BXPC3 cells, unloaded chitosan NBs showed high biocompatibility whereas they showed in-vitro cytotoxic effect once loaded with doxorubicin. In-vivo experiments, in PDAC xenograft model, showed that AT101 is able to target GPC1 when conjugated to chitosan NBs, thus increasing their specific delivery to GPC1-expressing cells of BXPC3 tumor, as compared to chitosan NBs not conjugated to AT101 (p = 0.0043 at 24 h). In-vivo experiments in the same model using chitosan NBs loaded with doxorubicin and conjugated or not with AT101 highlighted the ability of the 2 formulations to slow tumor growth and increase mouse survival compared to free doxorubicin (p = 0.0053 and p = 0.0001, respectively). Conjugation with AT101 further reduced tumor growth and increased survival of treated mice (p = 0.0059). Both chitosan NBs loaded with doxorubicin were able to reduce free doxorubicin toxicity effects. Ex-vivo RNA-seq analysis of extracted BXPC3 tumor masses revealed that AT101 conjugation of chitosan NBs was mainly associated with enhanced xenobiotic metabolism of tumor cells and increased leukocyte migration and proliferation in the tumor microenvironment. In conclusion, the anti-GPC1 AT101 antibody can be used as targeting agent for chemotherapeutic-loaded chitosan NBs for PDAC treatment.

    2026Biomedicine & Pharmacotherapy(2026)
    引用
    AI阅读
    加入学术空间
    3Pan-enteric Capsule Endoscopy in Crohn’s Disease: Impact on Therapeutic Decisions and Inter-Observer Agreement in a Multicentre Case-Based Study
    Carlo Calabrese, Nikolas Dussias,Fernando Rizzello,Paolo Gionchetti,Alessandro Armuzzi,Marco Daperno,Antonio Rispo,Chiara Ricci, Francesco Simone Conforti,Patrizia Alvisi,Erasmo Miele,Matteo Bramuzzo,

    Background and study aims Pan-enteric capsule endoscopy (CE) provides a comprehensive mucosal assessment of both the small bowel and colon in Crohn's disease (CD). However, its incremental impact on structured clinical decision-making and inter-observer agreement remains insufficiently defined. We aimed to evaluate whether the availability of CE findings influences therapeutic decisions, risk stratification and monitoring strategies in patients with CD. Patients and methods We performed a multicentre, retrospective, paired case-based study including 50 real-world CD cases (35 adults, 15 paediatric). For each case, two anonymised vignettes were generated: one incorporating clinical, biochemical and cross-sectional imaging data without CE, and one additionally including CE findings. Ten experienced inflammatory bowel disease (IBD) gastroenterologists (six adult, four paediatric) independently reviewed all vignettes in randomised order using a structured questionnaire. The primary outcome was change in therapeutic decision-making after disclosure of CE findings. Secondary outcomes included changes in risk stratification, assessment of treatment efficacy, timing of follow-up, confidence in decision-making and inter-observer agreement. Results Access to CE findings significantly modified risk assessment and treatment selection. Overall, 53.3% of risk-stratification responses and 56.7% of treatment decisions changed, with a consistent shift towards higher perceived risk and treatment escalation (p < 0.0001 for both). CE also altered monitoring strategies, increasing reliance on endoscopic/CE-based assessment (change rate 36.7%; p < 0.0001), and modestly shortened planned follow-up intervals (change rate 18.5%; p = 0.0366). Confidence scores showed no significant overall shift (p = 0.2700), despite 41.6% of individual ratings changing. Inter-observer agreement improved from fair to moderate across several domains when CE results were available. No cases with isolated colonic CD were included in the final case set, and no capsule retention occurred in the included cohort. Conclusions In this multicentre paired case-based study, pan-enteric CE substantially influenced risk stratification, treatment selection and monitoring plans in CD, while improving inter-observer agreement across several decision domains. These findings indicate that CE meaningfully affects structured clinical decision-making in selected patients, particularly when small-bowel involvement is suspected or when conventional investigations are discordant. Prospective longitudinal studies are needed to determine whether CE-guided decisions translate into improved clinical outcomes.

    2026Endoscopy international open(2026)
    引用
    AI阅读
    加入学术空间
    4ACUTE GRAFT-VERSUS-HOST DISEASE REQUIRING SECOND-LINE THERAPY AFTER PEDIATRIC ALLOGENEIC HCT IN THE PRE-RUXOLITINIB ERA: A RETROSPECTIVE AIEOP ANALYSIS
    Stella Boghen,Daria Pagliara,Mattia Algeri,Adriana Balduzzi,Simone Cesaro,Alessandra Biffi,Maura Faraci,Giovanna Giorgiani,Riccardo Masetti,Natalia Maximova,Maria Cristina Menconi,Pietro Merli,
    2026BONE MARROW TRANSPLANTATION(2026)
    引用
    AI阅读
    加入学术空间
    5Il Graffio
    Alessandro Ventura

    La speranza e il mestiere del medico

    2026Medico e Bambino(2026)
    引用
    AI阅读
    加入学术空间
    立即登录,查看全部 1093 篇论文

    合作机构(99)

    的里雅斯特大学合作论文 313
    意大利科学领域恢复与治疗研究所合作论文 69
    帕多瓦大学合作论文 38
    圣巴比诺·杰苏儿童医院合作论文 29
    博洛尼亚大学合作论文 22
    Burlo Garofolo Pediatric Institute合作论文 21
    都灵大学合作论文 16
    那不勒斯费德里克二世大学合作论文 15
    热那亚大学合作论文 14
    IRCCS 基金会 Ca' Granda Ospedale Maggiore Policlinico合作论文 14

    机构统计